Subgroup |
Numbers of patients |
True
positives |
False negatives |
False positives |
True negatives |
Sensitivity |
Specificity |
|
No. |
No. |
No. |
No. |
No. |
Percent (95%CI) |
Percent (95% CI) |
Patient population |
|
|
|
|
|
|
|
Full study cohort |
3’658 |
168 |
27 |
62 |
3’401 |
86.2 (80.5, 90.7) |
98.2 (97.7, 98.6) |
Inpatients |
1’085 |
80 |
14 |
15 |
976 |
85.1 (76.3, 91.6) |
98.5
(97.5, 99.2) |
Outpatients* |
2’573 |
88 |
13 |
47 |
2’438 |
87.1 (79.0, 93.0) |
98.1
(97.5, 98.6) |
Gender |
|
|
|
|
|
|
|
Male |
1’147 |
81 |
6 |
18 |
1’042 |
93.1 (85.6, 97.4) |
98.3 (97.3,
99.0) |
Female |
2’478 |
87 |
21 |
43 |
2’348 |
80.6 (71.8, 87.5) |
98.2 (97.6,
98.7) |
Age |
|
s |
|
|
|
|
|
< 50 years |
2’201 |
89 |
17 |
42 |
2’070 |
84.0 (75.6, 90.4) |
98.0 (97.3, 98.6) |
> 50 years |
1’457 |
79 |
10 |
20 |
1’348 |
88.8 (80.3,
94.5) |
98.5 (97.8, 99.1) |
Symptoms |
|
|
|
|
|
|
|
Any symptom |
1’985 |
143 |
25 |
39 |
1’751 |
85.1 (78.8, 90.1) |
97.8
(97.0, 98.5) |
No symptoms |
2’473 |
88 |
13 |
47 |
2’425 |
87.1 (79.0, 93.0) |
98.1
(97.5, 98.6) |
Days since PCR |
|
|
|
|
|
|
|
≥ 28 |
3’116 |
96 |
14 |
55 |
2’951 |
87.3 (79.6, 92.9) |
98.2 (97.6,
98.6) |
≥ 21 |
3’205 |
107 |
15 |
56 |
3’027 |
87.7 (80.5, 93.0) |
98.2 (97.7,
98.6) |
≥ 14 |
3’304 |
128 |
15 |
57 |
3’104 |
89.5 (83.3, 94.0) |
98.2 (97.7,
98.6) |